España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Kymera Therapeutics
KYMR
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$43.70
3.09
7.61%
At close: -
$43.70
0.00
0.00%
After Hours: 4:00 PM EDT
Get Report
Comment
Kymera Therapeutics (KYMR) Forecast
News
Earnings
Kymera Therapeutics (KYMR) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Kymera Therapeutics (NASDAQ:KYMR) Stock
Kymera Therapeutics Stock (NASDAQ: KYMR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, January 21, 2025
Kymera Therapeutics shares are trading higher...
Benzinga Newsdesk
Stephens & Co. Reiterates Overweight on Kymer...
Benzinga Newsdesk
Tuesday, January 14, 2025
Kymera Therapeutics shares are trading higher...
Benzinga Newsdesk
Kymera Therapeutics Targets 2025 Milestones w...
Benzinga Newsdesk
Friday, December 27, 2024
Leerink Partners Maintains Outperform on Kyme...
Benzinga Newsdesk
Tuesday, December 10, 2024
BTIG Initiates Coverage On Kymera Therapeutic...
Benzinga Newsdesk
Friday, December 06, 2024
BMO Capital Initiates Coverage On Kymera Ther...
Benzinga Newsdesk
Monday, December 02, 2024
Wells Fargo Upgrades Kymera Therapeutics to O...
Benzinga Newsdesk
Monday, November 18, 2024
Stephens & Co. Initiates Coverage On Kymera T...
Benzinga Newsdesk
Wednesday, November 06, 2024
Morgan Stanley Maintains Equal-Weight on Kyme...
Benzinga Newsdesk
Monday, November 04, 2024
UBS Maintains Buy on Kymera Therapeutics, Low...
Benzinga Newsdesk
Friday, November 01, 2024
Guggenheim Maintains Buy on Kymera Therapeuti...
Benzinga Newsdesk
The Latest Analyst Ratings For Kymera Therapeutics
Benzinga Insights
Truist Securities Reiterates Buy on Kymera Th...
Benzinga Newsdesk
Thursday, October 31, 2024
Kymera Therapeutics shares are trading lower ...
Benzinga Newsdesk
Kymera Therapeutics Q3 2024 GAAP EPS $(0.82) ...
Benzinga Newsdesk
Wednesday, October 30, 2024
Preview: Kymera Therapeutics's Earnings
Benzinga Insights
Insights Ahead: Kymera Therapeutics's Quarterly Earnings
Benzinga Insights
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Vandana Singh
Thursday, October 24, 2024
Kymera Therapeutics Has Initiated Dosing In P...
Benzinga Newsdesk
Wednesday, October 23, 2024
Kymera Therapeutics Announced That New Precli...
Benzinga Newsdesk
Wednesday, October 09, 2024
The FDA Clears Kymera Therapeutics' Investiga...
Benzinga Newsdesk
Friday, September 27, 2024
The Analyst Landscape: 7 Takes On Kymera Therapeutics
Benzinga Insights
Oppenheimer Maintains Outperform on Kymera Th...
Benzinga Newsdesk
Wednesday, September 25, 2024
Kymera Therapeutics Announced The Presentatio...
Benzinga Newsdesk
Monday, September 09, 2024
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Benzinga Insights
Monday, August 26, 2024
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Avi Kapoor
Wolfe Research Upgrades Kymera Therapeutics t...
Benzinga Newsdesk
Tuesday, August 20, 2024
Kymera Therapeutics Raises $225M Via Upsized ...
Benzinga Newsdesk
Monday, August 19, 2024
Kymera Therapeutics shares are trading lower ...
Benzinga Newsdesk
Kymera Therapeutics Begins Public Offering Of...
Benzinga Newsdesk
Wednesday, August 14, 2024
Morgan Stanley Maintains Equal-Weight on Kyme...
Benzinga Newsdesk
Monday, August 12, 2024
Unveiling 6 Analyst Insights On Kymera Therapeutics
Benzinga Insights
Wells Fargo Maintains Equal-Weight on Kymera ...
Benzinga Newsdesk
Wednesday, August 07, 2024
Kymera Therapeutics' Cash Balance Of $702M Ex...
Benzinga Newsdesk
Kymera Therapeutics Q2 2024 GAAP EPS $(0.58) ...
Benzinga Newsdesk
Sunday, July 14, 2024
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
Lekha Gupta
Wednesday, July 10, 2024
Oppenheimer Maintains Outperform on Kymera Th...
Benzinga Newsdesk
Kymera Therapeutics Surges 23.4%: Is This an Indication of Further Gains?
Zacks
Tuesday, July 09, 2024
B. Riley Securities Maintains Neutral on Kyme...
Benzinga Newsdesk
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
Kymera shares are trading higher after the co...
Benzinga Newsdesk
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
Monday, July 08, 2024
Kymera Intends To Expand Hidradenitis Suppura...
Benzinga Newsdesk
Monday, June 17, 2024
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Kymera ...
Benzinga Newsdesk
Friday, June 14, 2024
Kymera Therapeutics Shares New Clinical Data ...
Benzinga Newsdesk
Monday, June 03, 2024
HC Wainwright & Co. Reiterates Buy on Kymera ...
Benzinga Newsdesk
Reported Saturday, Kymera Therapeutics Showca...
Benzinga Newsdesk
Friday, May 24, 2024
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
